Precision medicine in relapsed or refractory pediatric solid tumors: a collaborative Spanish initiative
Tóm tắt
Understanding pediatric cancer biology is a huge challenge in continuous development that is currently being implemented into the clinical practice thanks to the new high throughput technologies integrated by personalized medicine. We present the results of the Precision Medicine program for children and adolescents with solid tumors in relapse/progression carried out in University La Fe Hospital (Valencia) from 2014. This is the first Spanish experience in precision medicine published in pediatric oncology. Study enrollment was offered to all patients having a refractory or relapsed solid tumor and an available biopsy treated in La Fe Hospital (Valencia, Spain) or in other Spanish pediatric oncologic center. Eighty four patients were finally studied. The commercial Human Comprehensive Cancer GeneReadDNAseq Targeted genes Panel (Qiagen©) was sequenced in fresh/frozen samples. Variants considered pathogenic or likely pathogenic were classified using the algorithm published by Parsons et al. based on perceived clinical utility. Thirteen of 84 patients (15%) received therapeutic recommendations due to an actionable variant detected and three patients received prognosis information based on sequencing results. Precision medicine projects based on targetable gene panel approximations can obtain translatable information to pediatric patients with reasonable efforts. This approach lowers economic expenses and reduces time of response with respect to whole exome sequencing. Since the translation to the clinical practice is the main objective of these projects, limiting the number of relatively well-known biological markers will allow us to transfer similar amount of information with less economic and human effort.
Tài liệu tham khảo
Van Dijk EL, Auger H, Jaszczyszyn Y, Thermes C. Ten years of next-generation sequencing technology. Trends Genet. 2014;30(9):418–26.
Ross JS, Cronin M. Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol. 2011;136(4):527–39.
Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, et al. The Cancer genome atlas pan-Cancer analysis project. Nat Genet. 2013;45(10):1113–20.
Banerji U, Workman P. Critical parameters in targeted drug development: the pharmacological a1.udit trail. SeminOncol. 2016;43(4):436–45.
Bartholomew C, Eastlake L, Dunn P, Yiannakis D. EGFR targeted therapy in lung cancer; an evolving story. Respir Med Case Rep. 2017;20:137–40.
Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Update on PARP inhibitors in breast Cancer. Curr Treat Options in Oncol. 2018;19(5):21.
Maximiano S, Magalhães P, Guerreiro MP, Morgado M. Trastuzumab in the treatment of breast Cancer. BioDrugs. 2016;30(2):75–86.
Mackiewicz J, Mackiewicz A. BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients. Contemp Oncol (Pozn). 2018;22(1A):68–72.
Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, et al. Clinical Cancer advances 2016: annual report on progress against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2016;34(9):987–1011.
Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Blankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.
Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, et al. Integrative clinical sequencing in themanagement of refractory or relapsed cancer in youth. JAMA. 2015;314:913–25.
Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, et al. Multicenter feasibility study oftumor molecular profiling to inform therapeutic decisions in advanced pediatricsolid tumors: the individualized Cancer therapy (iCat) study. JAMA Oncol. 2016;2:608–15.
Oberg JA, Glade Bender JL, Sulis ML, Pendrick D, Sireci AN, Hsiao SJ, et al. Implementation of next generationsequencing into pediatric hematology-oncology practice: moving beyondactionable alterations. Genome Med. 2016;8:133.
Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, et al. Diagnostic yield of clinical tumor andgermline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016;2:616–24.
Worst BC, van Tilburg CM, Balasubramanian GP, Fiesel P, Witt R, Freitag A, et al. Next-generationpersonalised medicine for high-risk paediatric cancer patients – the INFORM pilot study. Eur J Cancer. 2016;65:91–101.
Harttrampf AC, Lacroix L, Deloger M, Deschamps F, Puget S, Auger N, et al. MOlecular Screening for Cancer Treatment Optimization (MOSCATO-01) in pediatric patients: a single institutional prospective molecular stratification trial. Clin Cancer Res. 2017;23:6101–12.
Pincez T, Clément N, Lapouble E, Pierron G, Kamal M, Bieche I, et al. Feasibility and clinical integration ofmolecular profiling for target identification in pediatric solid tumors. Pediatr Blood Cancer. 2017;64:e26365.
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.
Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric Cancer. N Engl J Med. 2015;373(24):2336–46.
Seibel NL, Janeway K, Allen CE, Chi SN, Cho YJ, Glade Bender JL, et al. Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017;41(3):194–200.
Mody R, Prensner JR, Everett J, Parsons DW, Chinnaiyan AM. Precision medicine in pediatric oncology: lessons learned and next steps. Pediatr Blood Cancer. 2017;64(3). https://doi.org/10.1002/pbc.26288.
Zeng Y, Feldman AL. Genetics of anaplastic large cell lymphoma. Leuk Lymphoma. 2016;57(1):21–7.
Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and thesearch for new cancer associated genes. Nature. 2013;499(7457):214e8.
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes science. 2013;339(6127):1546e58.
Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015;47(8):864–71.
Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, et al. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015;47(8):872–7.
Morrissy AS, Garzia L, Shih DJ, Zuyderduyn S, Huang X, Skowron P, et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016;529(7586):351–7.
Tran TH, Shah AT, Loh ML. Precision medicine in pediatric oncology: translating genomic discoveries into optimized therapies. Clin Cancer Res. 2017;23(18):5329–38.
Forrest SJ, Geoerger B, Janeway KA. Precision medicine in pediatric oncology. Curr Opin Pediatr. 2018;30(1):17–24.
Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer genome and transcriptome analyses of 1,699paediatricleukaemias and solid tumours. Nature. 2018;555(7696):371–6.
Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood Cancers. Nature. 2018;555(7696):321–7.
Lyman GH, Moses HL. Biomarker tests for molecularly targeted therapies-the key to unlocking precision medicine. N Engl J Med. 2016;375(1):4–6.
Graig LA, Phillips JK, Moses HL. Biomarker tests for molecularly targeted therapies: key to unlocking precision medicine. N Engl J Med. 2016;375(1):4–6.